Rezolute Shares Rise on Positive Phase 3 Trial for Tumor Hyperinsulinism Drug
By Dr. Zubair Khalid, DVM, MS, PhD ·
Rezolute announced that its experimental therapy ersodetug met the primary endpoint in a phase 3 clinical trial for tumor hyperinsulinism. The positive result lifted the biotech’s stock ahead of a planned meeting with the U.S. Food and Drug Administration regarding a potential approval filing for a separate indication.
Tumor hyperinsulinism is a rare condition in which insulin-producing tumors cause dangerously low blood sugar. The phase 3 study evaluated ersodetug in patients with this disorder. Rezolute has not disclosed specific data from the trial, but the company stated the study achieved its main goal.
The company is now preparing for an FDA meeting to discuss a potential New Drug Application for ersodetug in another indication. The exact timing and scope of that filing have not been announced.
Why it matters: Tumor hyperinsulinism is a difficult-to-treat metabolic disorder with limited approved therapies. A successful phase 3 result for ersodetug could offer a new treatment option for patients who currently rely on surgery or off-label medications. For the biotech industry, the win also demonstrates the potential of antibody-based therapies to address rare endocrine diseases, an area where drug development is often high-risk but medically urgent.
Source: original report